Gilead Sciences, Inc. (NASDAQ:GILD)‘s stock had its “buy” rating reissued by investment analysts at William Blair in a research note issued on Thursday.

Other research analysts also recently issued reports about the stock. Jefferies Group LLC restated a “hold” rating and set a $80.00 target price on shares of Gilead Sciences in a research report on Tuesday, July 11th. Berenberg Bank set a $96.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Thursday. BMO Capital Markets restated an “outperform” rating and set a $82.00 target price (up from $72.00) on shares of Gilead Sciences in a research report on Thursday, July 27th. Robert W. Baird restated an “outperform” rating and set a $87.00 target price on shares of Gilead Sciences in a research report on Thursday, July 13th. Finally, J P Morgan Chase & Co restated an “overweight” rating and set a $82.00 target price on shares of Gilead Sciences in a research report on Tuesday, July 4th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Gilead Sciences presently has a consensus rating of “Buy” and an average price target of $85.64.

Shares of Gilead Sciences (NASDAQ GILD) traded up 1.97% during trading on Thursday, reaching $81.59. The company had a trading volume of 15,565,183 shares. The stock has a market capitalization of $106.55 billion, a price-to-earnings ratio of 8.86 and a beta of 1.14. The company’s 50 day moving average is $82.70 and its 200-day moving average is $72.55. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $86.27.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. The firm had revenue of $7.14 billion for the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business’s quarterly revenue was down 8.2% compared to the same quarter last year. During the same period in the previous year, the company earned $3.08 earnings per share. On average, equities research analysts anticipate that Gilead Sciences will post $8.74 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was first published by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/19/gilead-sciences-inc-gild-given-buy-rating-at-william-blair.html.

In other news, EVP Gregg H. Alton sold 40,000 shares of the company’s stock in a transaction dated Friday, July 21st. The shares were sold at an average price of $74.00, for a total transaction of $2,960,000.00. Following the completion of the transaction, the executive vice president now owns 137,488 shares in the company, valued at $10,174,112. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $82.56, for a total transaction of $6,054,372.48. The disclosure for this sale can be found here. Insiders have sold 486,819 shares of company stock valued at $39,298,919 in the last 90 days. Insiders own 1.30% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. grew its position in Gilead Sciences by 1.9% in the 2nd quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock valued at $7,425,281,000 after buying an additional 1,937,031 shares in the last quarter. Vanguard Group Inc. grew its position in Gilead Sciences by 2.4% in the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after buying an additional 2,148,697 shares in the last quarter. Bank of New York Mellon Corp grew its position in Gilead Sciences by 1.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock valued at $2,185,784,000 after buying an additional 310,607 shares in the last quarter. FMR LLC grew its position in Gilead Sciences by 1.1% in the 2nd quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock valued at $1,630,581,000 after buying an additional 258,005 shares in the last quarter. Finally, Parnassus Investments CA grew its position in Gilead Sciences by 37.4% in the 1st quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock valued at $1,110,228,000 after buying an additional 4,556,901 shares in the last quarter. Hedge funds and other institutional investors own 73.97% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.